Universidad Peruana Cayetano Heredia
Pharmacokinetics of rifampin in peruvian tuberculosis patients with and without comorbid diabetes or HIV
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Requena-Méndez, A. | |
| dc.contributor.author | Davies, G. | |
| dc.contributor.author | Ardrey, A. | |
| dc.contributor.author | Jave, O. | |
| dc.contributor.author | López-Romero, S.L. | |
| dc.contributor.author | Ward, S.A. | |
| dc.contributor.author | Moore, David Alexander James | |
| dc.date.accessioned | 2022-01-18T19:26:53Z | |
| dc.date.available | 2022-01-18T19:26:53Z | |
| dc.date.issued | 2012 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/10992 | |
| dc.description.abstract | For drug-compliant patients, poor responses to tuberculosis (TB) treatment might be attributable to subtherapeutic drug concentrations. An impaired absorption of rifampin was previously reported for patients with diabetes mellitus (DM) or HIV. The objectives of this study were to determine whether TB drug pharmacokinetics differed in Peruvian TB patients withDMor HIV. In this cross-sectional study, TB patients, recruited from health centers in Lima, Peru, had blood samples taken at 2 and 6 h after directly observed TB drug ingestion, to determine plasma concentrations of rifampin. Of 105 patients, 50 had TB without a comorbidity, 26 had coexistent DM, and 29 had coexistent HIV. Unexpectedly, the overall median 2- and 6-h levels of rifampin were 1.6 and 3.2 mg/liter, respectively, and the time to the peak concentration was 6 h (slow absorber) instead of 2 h (fast absorber) for 61 patients (62.2%). The geometric mean peak concentration of drug in serum (C max) was significantly higher in fast absorbers than in slow absorbers (5.0 versus 3.8 mg/liter; P = 0.05). The rifampin C max was significantly lower in male patients than in female patients (3.3 versus 6.3 mg/liter; P < 0.001). Neither slow nor fast absorbers with comorbidities (DM or HIV) had significantly different Cmax results compared to those of TB patients without comorbidities. An analysis of variance regression analysis showed that female gender (P < 0.001) and the time to maximum concentration of drug in serum (T max) at 2 h (P =0.012) were independently correlated with increased exposure to rifampin. Most of this Peruvian study population exhibited rifampin pharmacokinetics different from those conventionally reported, with delayed absorption and low plasma concentrations, independent of the presence of an HIV or DM comorbidity. | en_US |
| dc.language.iso | eng | |
| dc.publisher | American Society for Microbiology | |
| dc.relation.ispartofseries | Antimicrobial Agents and Chemotherapy | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | Humans | en_US |
| dc.subject | Controlled Study | en_US |
| dc.subject | Major Clinical Study | en_US |
| dc.subject | Sex Difference | en_US |
| dc.subject | Comorbidity | en_US |
| dc.subject | Rifampicin | en_US |
| dc.subject | HIV Infections | en_US |
| dc.subject | Human Immunodeficiency Virus Infection | en_US |
| dc.subject | Sex Factors | en_US |
| dc.subject | Treatment Outcome | en_US |
| dc.subject | Mycobacterium Tuberculosis | en_US |
| dc.subject | Tuberculosis | en_US |
| dc.subject | Tuberculosis Pulmonary | en_US |
| dc.subject | Antitubercular Agents | en_US |
| dc.subject | Treatment Response | en_US |
| dc.subject | Blood Sampling | en_US |
| dc.subject | Diabetes Mellitus | en_US |
| dc.subject | Rifampin | en_US |
| dc.subject | Maximum Plasma Concentration | en_US |
| dc.subject | Drug Absorption | en_US |
| dc.subject | Time To Maximum Plasma Concentration | en_US |
| dc.subject | Diabetes Complications | en_US |
| dc.subject | Directly Observed Therapy | en_US |
| dc.subject | Regression Analysis | en_US |
| dc.title | Pharmacokinetics of rifampin in peruvian tuberculosis patients with and without comorbid diabetes or HIV | en_US |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | https://doi.org/10.1128/AAC.06059-11 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.21 | |
| dc.relation.issn | 1098-6596 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
